Seer, Inc. Reports Strong Q2 2025 Growth and Innovations

Seer, Inc. ( (SEER) ) has released its Q2 earnings. Here is a breakdown of the information Seer, Inc. presented to its investors.

Seer, Inc. is a leading life sciences company specializing in proteomics, offering innovative solutions that provide unprecedented insights with its Proteograph Product Suite. The company operates within the biotechnology sector and is known for its disruptive approach to proteomics research.

In its second quarter of 2025, Seer, Inc. reported a notable 32% increase in revenue year-over-year, reaching $4.1 million. The company also launched its new high-throughput Proteograph ONE assay and SP200 automation instrument, which are expected to enhance the scalability and efficiency of their platform.

Key financial highlights from the report include a gross profit of $2.1 million with a gross margin of 52%, and a reduction in operating expenses by 21% compared to the previous year. Despite a net loss of $19.4 million, this marks an improvement from the $22.9 million loss in the same period last year. The company ended the quarter with approximately $263.3 million in cash, cash equivalents, and investments.

Strategically, Seer announced a collaboration with Korea University to conduct a large-scale proteomics study aimed at developing AI-driven cancer diagnostics. The company’s focus on innovation is further evidenced by accelerated third-party validation through impactful data presentations and publications.

Looking forward, Seer maintains its full-year 2025 revenue guidance in the range of $17 million to $18 million, indicating continued growth and confidence in its strategic direction. The management remains committed to transforming the field of proteomics, despite ongoing macroeconomic challenges affecting its customer base.